Expanding perspective: considering opioids in the management of dyspnoea in end-stage heart failure
Correspondence to Dr Jill M Steiner, Cardiology, University of Washington Medical Center, Seattle, WA 98195, USA; jills8@cardiology.washington.edu Heart failure is a chronic and progressive disease often accompanied by burdensome symptoms that limit quality of life. Over two-thirds of patients with...
Gespeichert in:
| Veröffentlicht in: | Heart (British Cardiac Society) 2023-07, Vol.109 (14), p.1048-1049 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1049 |
|---|---|
| container_issue | 14 |
| container_start_page | 1048 |
| container_title | Heart (British Cardiac Society) |
| container_volume | 109 |
| creator | Schlenker, Kathryn A Steiner, Jill M |
| description | Correspondence to Dr Jill M Steiner, Cardiology, University of Washington Medical Center, Seattle, WA 98195, USA; jills8@cardiology.washington.edu Heart failure is a chronic and progressive disease often accompanied by burdensome symptoms that limit quality of life. Over two-thirds of patients with end-stage heart failure experience dyspnoea.1 The experience of breathlessness can be terrifying for patients and is a major contributor to psychological distress in this population.2 Opioids are therefore a standard part of dyspnoea management at the end of life in an attempt to decrease the experience of air hunger. For patients with heart failure to be considered nearing end of life and hospice eligible (prognosis of less than 6 months), they must have class IV symptoms, indicating the presence of symptoms at rest and discomfort with any physical activity. |
| doi_str_mv | 10.1136/heartjnl-2023-322436 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2786101263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2786101263</sourcerecordid><originalsourceid>FETCH-LOGICAL-b450t-45f5b861fb0d47f9c92f07695f9c2c0b630b95ee072f28312ffb46fb9beea4123</originalsourceid><addsrcrecordid>eNp9kU1rFzEQxoMotla_gUjAi5fVvG_iTUp9gYIXBW8h2Z20-bObrMlusd_erP9WwUNPM8zzm2cGHoReUvKWUq7eXYMr6yFNHSOMd5wxwdUjdEqF0m1EfzxuPZeyU4T3J-hZrQdCiDBaPUUnXGmjeyJP0XDxa3FpjOkKL1DqAsMab-A9HnKqcYSyC3mJOY4Vx4TXa8CzS-4KZkgrzgGPt3VJGdyuQhq7ujYR_3kOBxenrcBz9CS4qcKLu3qGvn-8-Hb-ubv8-unL-YfLzgtJ1k7IIL1WNHgyij6YwbBAemVka9lAvOLEGwlAehaY5pSF4IUK3ngAJyjjZ-jN0Xcp-ecGdbVzrANMk0uQt2pZ39wJZYo39PV_6CFvJbXvLNPMCE1Y_zDVa6mVomanxJEaSq61QLBLibMrt5YSu0dl76Oye1T2GFVbe3VnvvkZxr9L99k0gBwBPx_-HX7Q8zc8mqDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785866193</pqid></control><display><type>article</type><title>Expanding perspective: considering opioids in the management of dyspnoea in end-stage heart failure</title><source>MEDLINE</source><source>PubMed Central</source><creator>Schlenker, Kathryn A ; Steiner, Jill M</creator><creatorcontrib>Schlenker, Kathryn A ; Steiner, Jill M</creatorcontrib><description>Correspondence to Dr Jill M Steiner, Cardiology, University of Washington Medical Center, Seattle, WA 98195, USA; jills8@cardiology.washington.edu Heart failure is a chronic and progressive disease often accompanied by burdensome symptoms that limit quality of life. Over two-thirds of patients with end-stage heart failure experience dyspnoea.1 The experience of breathlessness can be terrifying for patients and is a major contributor to psychological distress in this population.2 Opioids are therefore a standard part of dyspnoea management at the end of life in an attempt to decrease the experience of air hunger. For patients with heart failure to be considered nearing end of life and hospice eligible (prognosis of less than 6 months), they must have class IV symptoms, indicating the presence of symptoms at rest and discomfort with any physical activity.</description><identifier>ISSN: 1355-6037</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heartjnl-2023-322436</identifier><identifier>PMID: 36898705</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and British Cardiovascular Society</publisher><subject>Analgesics, Opioid - therapeutic use ; Cardiology ; Disease ; Dyspnea ; Dyspnea - diagnosis ; Dyspnea - drug therapy ; Dyspnea - etiology ; Editorial ; Exercise ; Heart Failure ; Heart Failure - complications ; Heart Failure - drug therapy ; Humans ; Meta-analysis ; Narcotics ; Palliative Care ; Patients ; Physical fitness ; Quality of life ; Symptom management ; Systematic review</subject><ispartof>Heart (British Cardiac Society), 2023-07, Vol.109 (14), p.1048-1049</ispartof><rights>Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b450t-45f5b861fb0d47f9c92f07695f9c2c0b630b95ee072f28312ffb46fb9beea4123</citedby><cites>FETCH-LOGICAL-b450t-45f5b861fb0d47f9c92f07695f9c2c0b630b95ee072f28312ffb46fb9beea4123</cites><orcidid>0000-0001-6372-1356</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36898705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schlenker, Kathryn A</creatorcontrib><creatorcontrib>Steiner, Jill M</creatorcontrib><title>Expanding perspective: considering opioids in the management of dyspnoea in end-stage heart failure</title><title>Heart (British Cardiac Society)</title><addtitle>Heart</addtitle><addtitle>Heart</addtitle><description>Correspondence to Dr Jill M Steiner, Cardiology, University of Washington Medical Center, Seattle, WA 98195, USA; jills8@cardiology.washington.edu Heart failure is a chronic and progressive disease often accompanied by burdensome symptoms that limit quality of life. Over two-thirds of patients with end-stage heart failure experience dyspnoea.1 The experience of breathlessness can be terrifying for patients and is a major contributor to psychological distress in this population.2 Opioids are therefore a standard part of dyspnoea management at the end of life in an attempt to decrease the experience of air hunger. For patients with heart failure to be considered nearing end of life and hospice eligible (prognosis of less than 6 months), they must have class IV symptoms, indicating the presence of symptoms at rest and discomfort with any physical activity.</description><subject>Analgesics, Opioid - therapeutic use</subject><subject>Cardiology</subject><subject>Disease</subject><subject>Dyspnea</subject><subject>Dyspnea - diagnosis</subject><subject>Dyspnea - drug therapy</subject><subject>Dyspnea - etiology</subject><subject>Editorial</subject><subject>Exercise</subject><subject>Heart Failure</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Narcotics</subject><subject>Palliative Care</subject><subject>Patients</subject><subject>Physical fitness</subject><subject>Quality of life</subject><subject>Symptom management</subject><subject>Systematic review</subject><issn>1355-6037</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1rFzEQxoMotla_gUjAi5fVvG_iTUp9gYIXBW8h2Z20-bObrMlusd_erP9WwUNPM8zzm2cGHoReUvKWUq7eXYMr6yFNHSOMd5wxwdUjdEqF0m1EfzxuPZeyU4T3J-hZrQdCiDBaPUUnXGmjeyJP0XDxa3FpjOkKL1DqAsMab-A9HnKqcYSyC3mJOY4Vx4TXa8CzS-4KZkgrzgGPt3VJGdyuQhq7ujYR_3kOBxenrcBz9CS4qcKLu3qGvn-8-Hb-ubv8-unL-YfLzgtJ1k7IIL1WNHgyij6YwbBAemVka9lAvOLEGwlAehaY5pSF4IUK3ngAJyjjZ-jN0Xcp-ecGdbVzrANMk0uQt2pZ39wJZYo39PV_6CFvJbXvLNPMCE1Y_zDVa6mVomanxJEaSq61QLBLibMrt5YSu0dl76Oye1T2GFVbe3VnvvkZxr9L99k0gBwBPx_-HX7Q8zc8mqDg</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Schlenker, Kathryn A</creator><creator>Steiner, Jill M</creator><general>BMJ Publishing Group Ltd and British Cardiovascular Society</general><general>BMJ Publishing Group LTD</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6372-1356</orcidid></search><sort><creationdate>20230701</creationdate><title>Expanding perspective: considering opioids in the management of dyspnoea in end-stage heart failure</title><author>Schlenker, Kathryn A ; Steiner, Jill M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b450t-45f5b861fb0d47f9c92f07695f9c2c0b630b95ee072f28312ffb46fb9beea4123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analgesics, Opioid - therapeutic use</topic><topic>Cardiology</topic><topic>Disease</topic><topic>Dyspnea</topic><topic>Dyspnea - diagnosis</topic><topic>Dyspnea - drug therapy</topic><topic>Dyspnea - etiology</topic><topic>Editorial</topic><topic>Exercise</topic><topic>Heart Failure</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Narcotics</topic><topic>Palliative Care</topic><topic>Patients</topic><topic>Physical fitness</topic><topic>Quality of life</topic><topic>Symptom management</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schlenker, Kathryn A</creatorcontrib><creatorcontrib>Steiner, Jill M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Heart (British Cardiac Society)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schlenker, Kathryn A</au><au>Steiner, Jill M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expanding perspective: considering opioids in the management of dyspnoea in end-stage heart failure</atitle><jtitle>Heart (British Cardiac Society)</jtitle><stitle>Heart</stitle><addtitle>Heart</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>109</volume><issue>14</issue><spage>1048</spage><epage>1049</epage><pages>1048-1049</pages><issn>1355-6037</issn><eissn>1468-201X</eissn><abstract>Correspondence to Dr Jill M Steiner, Cardiology, University of Washington Medical Center, Seattle, WA 98195, USA; jills8@cardiology.washington.edu Heart failure is a chronic and progressive disease often accompanied by burdensome symptoms that limit quality of life. Over two-thirds of patients with end-stage heart failure experience dyspnoea.1 The experience of breathlessness can be terrifying for patients and is a major contributor to psychological distress in this population.2 Opioids are therefore a standard part of dyspnoea management at the end of life in an attempt to decrease the experience of air hunger. For patients with heart failure to be considered nearing end of life and hospice eligible (prognosis of less than 6 months), they must have class IV symptoms, indicating the presence of symptoms at rest and discomfort with any physical activity.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and British Cardiovascular Society</pub><pmid>36898705</pmid><doi>10.1136/heartjnl-2023-322436</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-6372-1356</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6037 |
| ispartof | Heart (British Cardiac Society), 2023-07, Vol.109 (14), p.1048-1049 |
| issn | 1355-6037 1468-201X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2786101263 |
| source | MEDLINE; PubMed Central |
| subjects | Analgesics, Opioid - therapeutic use Cardiology Disease Dyspnea Dyspnea - diagnosis Dyspnea - drug therapy Dyspnea - etiology Editorial Exercise Heart Failure Heart Failure - complications Heart Failure - drug therapy Humans Meta-analysis Narcotics Palliative Care Patients Physical fitness Quality of life Symptom management Systematic review |
| title | Expanding perspective: considering opioids in the management of dyspnoea in end-stage heart failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T01%3A33%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expanding%20perspective:%20considering%20opioids%20in%20the%20management%20of%20dyspnoea%20in%20end-stage%20heart%20failure&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.au=Schlenker,%20Kathryn%20A&rft.date=2023-07-01&rft.volume=109&rft.issue=14&rft.spage=1048&rft.epage=1049&rft.pages=1048-1049&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heartjnl-2023-322436&rft_dat=%3Cproquest_cross%3E2786101263%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785866193&rft_id=info:pmid/36898705&rfr_iscdi=true |